WPD is open to R&D and project-based collaborations with biotech, pharmaceutical, academic, clinical and technology partners in CNS oncology..

WPD is open to R&D and project-based collaborations with biotech, pharmaceutical, academic, clinical and technology partners. Areas of particular interest include glioblastoma and CNS oncology, blood–brain barrier delivery, targeted protein–drug conjugates, CMC and bioconjugation, translational studies, theranostics/radioligands, biomarkers and early clinical development. WPD can contribute its oncology platforms, receptor-targeting expertise and drug-development capabilities to jointly developed national or international projects.